Last month’s “Global Nature Index” reported worldwide research contributions by region. With 57,501 papers from 2014 in the “Index,” North America, North and West Europe, and East and Southeast Asia accounted for 91% of the total whole fractional count (WFC) of articles, at 19,425, 15,785 and 11,464, respectively. These regions accounted for most of the […]
In the US, Europe, Australia and Canada, 2014 biotech sales totaled $123.1 billion, rising 24.3%, with each country or region accounting for 76%, 19%, 5% and 0.2% of sales, respectively. Sales of Gilead Science’s hepatitis C drugs accounted for a sizable portion of revenues in 2014; adjusting for Gilead, growth for the industry was 12%. […]
By the University of Manchester’s estimates, $2.4 billion has been invested in graphene research. In 2014, Lux Research projected a 2025 global market of $349 million for the material; however, in 2013, sales of graphene totaled only $12 million. Manufacture of the material has accelerated, with total production capacity of graphene nanoplatelets in the Americas; […]
Based on the top 500 pharmaceutical and biotechnology companies, the 2020 global market for prescription drugs is forecast at $987 billion, with a compound annual growth rate (CAGR) of 4.8% from 2014 to 2020. Sales in 2014 grew to $743 billion, up 2.8%, and total R&D increased 3.1% to $141.6 billion. R&D is forecast to […]
US bulk chemical producers are benefiting from the rise in US shale gas output and subsequent lower gas prices. In contrast to producers in other regions that rely on oil products, such as naptha, for feedstock, US companies’ access to shale gas provides them with cheaper feedstock, including ethane. Commodities chemicals provider LyondellBasell is an […]
Using biomarkers from patients’ tumors in clinical trials may not be as reliable as genetic variation in determining who will benefit most from particular drug treatments. For example, the protein levels detected in a test may differ based the part of a tumor from which a biopsy was obtained and the extent of a cancer’s […]
A paper published this month estimated that each year in the US about $28.2 billion, or half of the total spending on preclinical research, is used for preclinical studies that are not reproducible. “[T]he existence and propagation of one or more errors, flaws, inadequacies or omissions . . . that prevent replication of results” were […]
The US FDA has finalized its 2012 drafts on biosimilarity with three guidance documents. The first guidance presents the approach for sponsors to obtain evidence showing biosimilarity and by the FDA in reviewing applications for biosimilars. It also provides some clarifications in its recommendations. It encourages frequent consultation with the FDA during the early stages […]
In the 20 or so years prior to 2000, forensic analysis of hair was used against defendants in about 2,500 US trials. Reviews of 342 of these cases by the US Justice Department and the FBI revealed that in 257 of 268 of these cases, 26 of 28 FBI examiners gave flawed testimony, overstating matches […]
More than 60 authors from the academic and industrial sectors have published a science and technology road map in the journal Nanoscale for graphene, related to 2-D crystals, other 2-D materials and hybrids. The authors are members of the Graphene Flagship, an international research initiative formed to take graphene from labs and into European society […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
